Du är här


PCI Biotech: Successful completion of the third dose cohort in the study for patients with inoperable bile duct cancer

Lysaker, 18 August 2015 - PCI Biotech (PCIB) the Norwegian biopharmaceutical
company, reported today that the treatment evaluation of the third dose
cohort is completed in the phase I/II study of Amphinex®-induced PCI of
gemcitabine followed by gemcitabine/cisplatin treatment in patients with
inoperable bile duct cancer (cholangiocarcinoma). No safety concerns were
observed at this dose level.

The Cohort Review Committee of clinical experts and company representatives
that evaluates the results and provides recommendation for the continuation
of the study has recommended that the study progress into the next dose in
accordance with the study protocol. Patients for the next dose cohort are
currently being screened and will be treated with Amphinex as soon as

Bile duct cancer is a rare disease and the company is working actively to
increase the patient recruitment rate. The eligible patient population has
been expanded to also include metastatic patients and further hospitals in
selected European countries are being added to the study.

About PCI Biotech
PCI Biotech is a cancer focused biopharmaceutical company headquartered in
Norway and listed on the Oslo Stock Exchange (Axess). The company is
developing therapeutic products based on its proprietary photochemical
internalization (PCI) technology. Originating from world leading research at
the Norwegian Radium Hospital, the PCI technology works by inducing triggered
endosomal release and may be used to unlock the true potential of a wide
array of therapeutic modalities, such as small molecules, vaccines and
nucleic acids.

The company currently has a bile duct cancer program in phase I/II clinical
development. Bile duct cancer is an orphan indication without any approved
medicinal products and a high medical need for better local treatments. It is
an indication well suited for PCI treatment, with easy light access for
intraluminal surface illumination through routine endoscopic methods and an
active generic drug (gemcitabine) significantly enhanced by PCI.

The company is also developing PCI as a CTL (Cytotoxic T Lymphocyte) induction
technology for therapeutic and prophylactic vaccination. It has been
demonstrated both in vivo and ex vivo that PCI significantly increases the
number of activated antigen-specific CTLs by enhancing the MHC I antigen
presentation of antigen presenting cells. When applied in the emerging field
of cancer immunotherapy, PCI can be used to enhance the important cytotoxic
effect of therapeutic cancer vaccines.

PCI Biotech follows a strategy to create value by improving the effect both of
existing cancer drugs and by realizing the large potential in new
therapeutics, including therapeutic vaccines.

For more information visit: www.pcibiotech.com
Contact information:
PCI Biotech Holding ASA, Strandveien 55, N-1366 Lysaker
Per Walday, CEO, pw@pcibiotech.no, Mobile: +47 917 93 429
Ronny Skuggedal, CFO, rs@pcibiotech.no, Mobile: +47 940 05 757

This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: PCI Biotech Holding via Globenewswire


Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.